WallStSmart

Boston Scientific Corp (BSX)vsLumexa Imaging Holdings, Inc. Common Stock (LMRI)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Boston Scientific Corp generates 1912% more annual revenue ($21.00B vs $1.04B). BSX leads profitability with a 17.5% profit margin vs -2.7%. BSX earns a higher WallStSmart Score of 70/100 (B-).

BSX

Strong Buy

70

out of 100

Grade: B-

Growth: 7.3Profit: 7.0Value: 5.3Quality: 5.5
Piotroski: 5/9Altman Z: 1.78

LMRI

Hold

35

out of 100

Grade: F

Growth: 4.7Profit: 3.0Value: 5.0Quality: 6.0
Piotroski: 7/9Altman Z: 0.57
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

BSXSignificantly Overvalued (-27.6%)

Margin of Safety

-27.6%

Fair Value

$39.07

Current Price

$46.66

$7.59 premium

UndervaluedFair: $39.07Overvalued

Intrinsic value data unavailable for LMRI.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BSX5 strengths · Avg: 8.2/10
Market CapQuality
$74.53B9/10

Large-cap with strong market position

PEG RatioValuation
0.758/10

Growing faster than its price suggests

Price/BookValuation
2.7x8/10

Reasonable price relative to book value

Operating MarginProfitability
22.9%8/10

Strong operational efficiency at 22.9%

Free Cash FlowQuality
$1.28B8/10

Generating 1.3B in free cash flow

LMRI2 strengths · Avg: 8.5/10
Debt/EquityHealth
0.259/10

Conservative balance sheet, low leverage

Price/BookValuation
1.8x8/10

Reasonable price relative to book value

Areas to Watch

BSX1 concerns · Avg: 4.0/10
Altman Z-ScoreHealth
1.784/10

Distress zone — elevated risk

LMRI4 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$1.19B3/10

Smaller company, higher risk/reward

Operating MarginProfitability
3.2%3/10

Operating margin of 3.2%

Return on EquityProfitability
-10.0%2/10

ROE of -10.0% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : BSX

The strongest argument for BSX centers on Market Cap, PEG Ratio, Price/Book. Profitability is solid with margins at 17.5% and operating margin at 22.9%. PEG of 0.75 suggests the stock is reasonably priced for its growth.

Bull Case : LMRI

The strongest argument for LMRI centers on Debt/Equity, Price/Book.

Bear Case : BSX

The primary concerns for BSX are Altman Z-Score.

Bear Case : LMRI

The primary concerns for LMRI are EPS Growth, Market Cap, Operating Margin.

Key Dynamics to Monitor

BSX profiles as a mature stock while LMRI is a turnaround play — different risk/reward profiles.

BSX is growing revenue faster at 7.5% — sustainability is the question.

BSX generates stronger free cash flow (1.3B), providing more financial flexibility.

Monitor MEDICAL DEVICES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

BSX scores higher overall (70/100 vs 35/100), backed by strong 17.5% margins. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Boston Scientific Corp

HEALTHCARE · MEDICAL DEVICES · USA

Boston Scientific Corporation, doing business as Boston Scientific, is a manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.

Lumexa Imaging Holdings, Inc. Common Stock

HEALTHCARE · MEDICAL DEVICES · USA

Lumexa Imaging Holdings, Inc. owns and operates diagnostic imaging centres in the United States. The company is headquartered in Raleigh, North Carolina.

Want to dig deeper into these stocks?